STAT+: The Race to Catch KRAS, Pancreatic Cancer’s ‘Greasy Ball,’ and Create the Most Promising Drug in Decades

Why It Matters

Daraxonrasib demonstrates that previously “undruggable” KRAS mutations can be effectively targeted, opening a multi‑billion‑dollar market and new therapeutic options for aggressive cancers.

Key Takeaways

• Daraxonrasib targets KRAS and related proteins in pancreatic cancer
• Patient Leanna Stokes saw extended survival in trial
• Revolution Medicines leads KRAS inhibitor pipeline with multiple candidates
• Early KRAS drugs showed limited durability and rapid resistance
• KRAS inhibitors poised to reshape treatment for lung, colorectal cancers

Pulse Analysis

The KRAS gene has long been a notorious obstacle in oncology, earning the nickname “the greasy ball” for its elusive binding pocket. Early attempts to inhibit KRAS, sparked by Kevan Shokat’s landmark discovery, yielded only modest benefits and rapid resistance, dampening investor enthusiasm for nearly two decades. However, the proof‑of‑concept that KRAS can be drugged sparked a cascade of research, with academic labs and biotech firms racing to refine molecular scaffolds that lock the protein in an inactive state.

Revolution Medicines’ daraxonrasib represents the latest iteration of this effort, combining a covalent binding mechanism with enhanced selectivity for the G12D and G12V KRAS mutants that dominate pancreatic adenocarcinoma. In a Phase 1/2 trial, patients like 36‑year‑old Leanna Stokes experienced tumor shrinkage and survival extensions far beyond historical benchmarks, prompting accelerated regulatory pathways. Early data suggest a manageable safety profile and activity across other KRAS‑driven malignancies, positioning daraxonrasib as a potential platform therapy for lung, colorectal and endometrial cancers.

The commercial implications are profound. Analysts project a KRAS inhibitor market exceeding $10 billion within five years, driven by high unmet need and the ability to pair these agents with immunotherapies or chemotherapy backbones. Competitors such as Mirati, Amgen and Pfizer are advancing their own pipelines, intensifying M&A interest and venture capital inflows. As the field matures, the focus will shift from single‑agent efficacy to combination strategies that forestall resistance, ultimately redefining standards of care for some of the deadliest cancers.